MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.esmoop.2026.108302

Медицинская библиотека · ESMO open · 2026

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

Roviello G, Ciccimarra F, Urabe F, Melichar B, Studentova H, Niedersuess-Beke D, Mota A, Büttner T, Gómez de Liaño A, Yano A, Myint Z W, Kopp R M, Zgura A, Pinto A, Angel M, Tural D, Kanesvaran R, Ürün Y, Molina-Cerrillo J, Marques Monteiro F S, Massari F, Fiala O, Santoni M, Antonuzzo L, Rizzo A

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Enfortumab vedotin (EV) is a standard treatment for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy and immune checkpoint inhibitors. However, reliable and clinically accessible prognostic tools for patients treated with EV remain limited. We evaluated the clinical prognostic performance of the HERO score in a large real-world cohort of EV-treated patients.

PATIENTS AND

METHODS

ARON-2EV is a retrospective multicenter cohort study including patients with mUC treated with EV after platinum-based chemotherapy and immune checkpoint inhibitors. The association between the HERO score, based on hemoglobin level and neutrophil-to-lymphocyte ratio, and survival outcomes (overall survival and progression-free survival) was assessed. Response analyses were considered exploratory.

RESULTS

A total of 548 patients with mUC treated with EV were included in the analysis. Median overall survival was 12.4 months and median progression-free survival was 6.8 months. The HERO score was associated with survival and response outcomes, with patients with a score of 2 experiencing the most favorable outcomes. These associations remained consistent across multivariable analyses.

CONCLUSIONS

In this large international real-world cohort, the HERO score was associated with survival and response outcomes in patients with mUC treated with EV, particularly through identification of a subgroup with a more favorable prognosis (score 2). However, discrimination between lower score categories was less pronounced. Further prospective refinement and evaluation of the HERO score are warranted, particularly in contemporary EV-based treatment strategies.

Для цитирования: Roviello G, Ciccimarra F, Urabe F, Melichar B, Studentova H, Niedersuess-Beke D, Mota A, Büttner T, Gómez de Liaño A, Yano A, Myint Z W, Kopp R M, Zgura A, Pinto A, Angel M, Tural D, Kanesvaran R, Ürün Y, Molina-Cerrillo J, Marques Monteiro F S, Massari F, Fiala O, Santoni M, Antonuzzo L, Rizzo A. Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).. ESMO open. 2026. DOI: 10.1016/j.esmoop.2026.108302.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.